Neurocrine Biosciences Inc vs Wendys Co — how do they compare? Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B), while Wendys Co trades at $7.63 (market cap $1.50B). The key difference: Neurocrine Biosciences Inc is far larger — about 11.6× Wendys Co's market cap, and Wendys Co pays a 7.13% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | WEN | |
|---|---|---|
Market Cap | $17.40B | $1.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $180.55 | $11.33 |
52-Week Low | $123.10 | $6.17 |
Enterprise Value | $16.49B | $5.31B |
Dividend Yield | — | 7.13% |
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →